Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB-Plasma System in comparison to quarantine plasma: 11 years’ experience (2014)

Peer-Reviewed Study · Politis C; Kavallierou L; Hantziara S; Parara M; Zervou E; Katsarou O; Hatzitaki M; Fountouli P; Gioka A; Tzioura K; Koumarianos S; Asariotou M; Richardson C · September 29, 2014

Politis C et al., 2014-09-29: Eleven years of Greek national haemovigilance data comparing methylene blue-treated fresh frozen plasma with quarantine plasma: adverse-event rates were about 6.8 times lower with MB-FFP, and all reactions in MB recipients were mild.

The incidence of adverse events was higher with Q-FFP (1:3620) than MB-FFP (1 : 24 593) by a factor of 6·79 [95% confidence interval (CI) 2·52-27·8].

Abstract

Politis C et al., 2014-09-29: Eleven years of Greek national haemovigilance data comparing methylene blue-treated fresh frozen plasma with quarantine plasma: adverse-event rates were about 6.8 times lower with MB-FFP, and all reactions in MB recipients were mild. Study type: national haemovigilance comparative cohort (observational), Greece, 2001-2011. Units/recipients: a national transfusion population (numbers of units not in the abstract). Product: MB-FFP made with the Theraflex MB-Plasma system. Comparator: quarantine FFP. Funding/COI not stated in retrieved abstract record. Caveat: observational, so residual confounding and reporting differences cannot be excluded. Study type: controlled study.